Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2024-04-18

FDA Approved: TRIUMEQ PD — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for TRIUMEQ PD (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare. This results in a labeling upda…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRIUMEQ PD (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)

Snippet

SUPPL AP for TRIUMEQ PD (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)